The Texas House of Representatives is considering House Bill 3256, which would legalize syringe exchange programs (SEPs) as a means of reducing the transmission of infectious and communicable diseases among people who inject drugs. On April 25, William Martin, director of the Drug Policy Program, appeared before the Texas House Committee on Public Health to testify in support of HB 3256. Martin also authored an op-ed in TribTalk supporting the establishment of SEPs.
Drug policy has experienced an interesting shift recently. Along with legalization of medical and recreational marijuana, many states are also reducing penalties for nonviolent drug offenses and placing greater focus on treatment for drug users. The emphasis on treatment and rehabilitation for drug users is the result of many factors, including recognition that the drug war has not reduced drug use, a desire to reduce the prison population and save money, and a surge in the rate of overdoses from opioid and heroin use. What remains to be seen is whether the current popularity of drug treatment will become a more permanent feature of drug policy. In this Baker Institute Viewpoints series, five experts on drug policy examine the question, “Is the current emphasis on treatment in drug policy a short-term trend or is it here to stay?”
Katharine Neill Harris, William MartinDecember 19, 2014
In this installment of Baker Institute Viewpoints, experts discuss the question, "What does jury nullification of marijuana cases in Texas indicate about the possibility of marijuana legalization?"
